Israel Hodish is an Endocrinology/Metabolic physician. OpenAlex indexes 56 publications with 1,246 citations (h-index 17); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3 Riverside Cir
Roanoke, VA 240164955
Telephone
540-224-5170Provider last certified this registry record 11 Sept 2025.
Clinical trials
- Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care
Sponsor: University of Michigan
- Efficacy and Safety of Frequently Modified Intensive Insulin
Sponsor: Hygieia, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20231 payment
- Xeris Pharmaceuticals, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
42.9%Statin19.2%Atorvastatin Calcium76%Rosuvastatin Calcium24%Part D<11 patientsCalcium channel blocker6.1%Amlodipine Besylate100%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
38.1%Biguanide (metformin)13.7%Metformin Hcl62%Metformin Hcl Er39%Part D<11 patientsInsulin Analog8.2%Lantus Solostar72%Novolog Flexpen28%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
13.1%l-Thyroxine13.1%Levothyroxine Sodium100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Scalable Application of Artificial Intelligence-Driven Insulin Titration Program to Transform Type 2 Diabetes Management
Diabetes Technology & Therapeutics
2024 - Challenging the 50‐50 rule for the basal‐bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control
Diabetes Obesity and Metabolism
2022
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
Mount Sinai Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”